The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
Asociación de inhibidores de SGLT-2 (Empagliflozina) con el desarrollo de deshidratación hipernatrémica: reporte de un caso
Diana Alegre-González, Sandra García-Guerreros, Sara Martínez-Hernández, Ana Yasmina Brito-Díaz, Marta Casañas-Martínez, Ramón Baeza-Trinidad
Abstract
Sodium-Glucose-Cotransporter -2 inhibitors (SGLT2 inhibitors) are a new class of drugs that reduce blood glucose levels by increasing glucose excretion and lowering blood pressure through natriuresis and plasma volumen contraction. Due to their beneficial effects, they are currently used in treatment of both diabetes mellitus and heart failure, leading to widespread use in recent years. Here, we present a case of a patient who experienced severe hypernatremic dehydration related to the initiation of treatment with iSGLT2 inhibitors.
Keywords
Resumen
Los inhibidores del cotransportador de sodio-glucosa-2 (inhibidores de iSGLT2) son una nueva clase de fa rmacos que reducen los niveles de glucosa en sangre al aumentar la excrecio n de glucosa y disminuir la presio n arterial a trave s de la natriuresis y la contraccio n del volumen plasma tico. Debido a sus efectos beneficiosos, actualmente se utilizan en el tratamiento tanto de la diabetes mellitus como de la insuficiencia cardí aca, lo que ha llevado a un uso generalizado en los u ltimos an os. En este artí culo, presentamos el caso de un paciente que presento una deshidratacio n hipernatre mica grave relacionada con el inicio del tratamiento con inhibidores de iSGLT2.
Palabras clave
References
1. Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine. 2016;53(2):364-72. doi: 10.1007/s12020-016-0943-4.
2. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
3. Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(4):416-27. doi: 10.1111/jdi.12644.
4. Gelbenegger G, Buchtele N, Schoergenhofer C, Roeggla M, Schwameis M. Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with Empagliflozin. Drug Saf Case Rep. 2017;4(1):17. doi: 10.1007/s40800-017-0058-8.
5. Molaschi M, Ponzetto M, Massaia M, Villa L, Scarafiotti C, Ferrario E. Hypernatremic dehydration in the elderly on admission to hospital. J Nutr Health Aging. 1997;1(3):156-60.
6. Popli S, Tzamaloukas AH, Ing TS. Osmotic diuresis-induced hypernatremia: better explained by solute-free water clearance or electrolyte-free water clearance? Int Urol Nephrol. 2014;46(1):207-10. doi: 10.1007/s11255-012-0353-3.
7. Sugiyama J, Ryuge A, Mitsubayashi K, Ito M, Matsumoto N, Takeuchi R, et al. Dapagliflozin induced hypernatremia via osmotic diuresis: a case report. CEN Case Rep. 2024;13(1):9-13. doi: 10.1007/s13730-023-00790-x.
8. Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabetes Metab Case Rep. 2015;2015:150042. doi: 10.1530/EDM-15-0042.
Submitted date:
05/04/2024
Reviewed date:
08/01/2024
Accepted date:
10/09/2024
Publication date:
10/23/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email